- Active, not recruiting
NCT01093196: Phase 3: EMN01- Len/Dex Vs Melphalan/Pred/Len Vs Cyclophosamide/Pred/Len - elderly NDMM
Updated: Sep 25, 2022
EMN01
European Myeloma Network
Newly Diagnosed Multiple Myeloma

NCT01093196: Phase 3: Len and Dex Vs Melphalan Prednisone and Len Vs Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients
NCT01093196: Phase 3: Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients
This is a multicenter, randomized, controlled, 3 arm parallel group study designed to evaluate the efficacy and safety of three all-oral combinations: lenalidomide with dexamethasone (Rd) in comparison with lenalidomide in association with MP (MPR) and lenalidomide in association with cyclophosphamide - prednisone (CPR) in newly diagnosed symptomatic MM patients. This protocol also provides a substudy designed to observe asymptomatic patients excluded to the protocol that in any case could be inserted in the study.
Sponsor
Fondazione EMN Italy Onlus
Home - European Myeloma Network (myeloma-europe.org)
ClinicalTrials.gov Identifier: NCT01093196
Official Title: A Phase 3, Intergroup Multicentre, Randomized, Controlled 3 Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide in Combination With Dexamethasone (RD) Versus Melphalan, Prednisone and Lenalidomide (MPR) Versus Cyclophosphamide, Pre